Lincoln Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.4 pts more than Nifty Microcap 250 and 8.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lincoln Pharmaceuticals has received board approval to re-appoint four directors, subject to shareholder approval at the upcoming AGM. Mr. Mahendra G. Patel (promoter, 45+ years of pharma experience) will continue as Managing Director for 5 years from October 1, 2025 to September 30, 2030. Mr. Hashmukh I. Patel will be re-appointed as Whole Time Director for the same 5-year period. Mr. Ashish R. Patel (son of Mr. Rajnikant G. Patel) and Mr. Munjal M. Patel (son of Mahendra G. Patel) will each be re-appointed as Whole Time Directors for 5 years from November 14, 2025 to November 13, 2030. All four are existing directors being re-appointed, and none are debarred by SEBI from holding directorship.
This is a routine continuity announcement with no change in leadership or board composition. Existing management, including the promoter family, continues for another five-year cycle, which is neutral for shareholders and unlikely to move the stock.